CIGNA approves Pegasys for PV and ET

Effective January 15 2012, Cigna covers Peginterferon Alfa-2a (Pegasys) for treatment of Polycythemia Vera (PV) and Essential Thrombocythemia (ET). For PV, approval is based on failure, contraindication, or intolerance to both phlebotomy and other myelosuppressive agents. 

The change in Cigna’s coverage policy resulted from a request by the MPN Research Foundation to amend its policy on Pegasys in light of the recent clinical trials showing the significant effectiveness in PV and ET patients. Click here for further details from Cigna on their coverage of Pegasys.